Matches in DBpedia 2016-04 for { <http://wikidata.dbpedia.org/resource/Q18359213> ?p ?o }
Showing triples 1 to 39 of
39
with 100 triples per page.
- Q18359213 subject Q15266187.
- Q18359213 subject Q8808791.
- Q18359213 subject Q8862272.
- Q18359213 subject Q8878420.
- Q18359213 abstract "PF-4455242 is a selective, short-acting (non-"inactivating") antagonist of the κ-opioid receptor. Discovered by Pfizer in 2009, it was pursued in a phase I clinical trial for the treatment of bipolar disorder, and was also investigated as a treatment for depression and substance abuse. However, development was stopped in September 2010 due to toxicology findings in animals that had been exposed to the drug for three months.".
- Q18359213 atcPrefix "None".
- Q18359213 casNumber "1202647-54-8".
- Q18359213 iupacName "2-Methyl-N-{[2’-(1-pyrrolidinylsulfonyl)-4-biphenylyl]methyl}-1-propanamine".
- Q18359213 pubchem "44599828".
- Q18359213 thumbnail PF-4455242.svg?width=300.
- Q18359213 wikiPageWikiLink Q1114982.
- Q18359213 wikiPageWikiLink Q131755.
- Q18359213 wikiPageWikiLink Q14897645.
- Q18359213 wikiPageWikiLink Q15266187.
- Q18359213 wikiPageWikiLink Q18204530.
- Q18359213 wikiPageWikiLink Q18344482.
- Q18359213 wikiPageWikiLink Q206921.
- Q18359213 wikiPageWikiLink Q285166.
- Q18359213 wikiPageWikiLink Q30612.
- Q18359213 wikiPageWikiLink Q3184856.
- Q18359213 wikiPageWikiLink Q410943.
- Q18359213 wikiPageWikiLink Q4340209.
- Q18359213 wikiPageWikiLink Q7218.
- Q18359213 wikiPageWikiLink Q8808791.
- Q18359213 wikiPageWikiLink Q8862272.
- Q18359213 wikiPageWikiLink Q8878420.
- Q18359213 wikiPageWikiLink Q909405.
- Q18359213 atcPrefix "None".
- Q18359213 casNumber "1202647".
- Q18359213 iupacName "2".
- Q18359213 pubchem "44599828".
- Q18359213 type ChemicalSubstance.
- Q18359213 type Drug.
- Q18359213 type ChemicalObject.
- Q18359213 type Thing.
- Q18359213 type Q8386.
- Q18359213 comment "PF-4455242 is a selective, short-acting (non-"inactivating") antagonist of the κ-opioid receptor. Discovered by Pfizer in 2009, it was pursued in a phase I clinical trial for the treatment of bipolar disorder, and was also investigated as a treatment for depression and substance abuse. However, development was stopped in September 2010 due to toxicology findings in animals that had been exposed to the drug for three months.".
- Q18359213 label "PF-4455242".
- Q18359213 depiction PF-4455242.svg.